BRIEF-Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals

NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc.

NRXP

0.00

June 24 (Reuters) - Kadima Neuropsychiatry Institute:

  • KADIMA NEUROPSYCHIATRY INSTITUTE FILES SUIT AGAINST NRX PHARMACEUTICALS (NASDAQ: NRXP), ALLEGING BREACH OF CONTRACT AND MISREPRESENTATION IN CONNECTION WITH ACQUISITION

  • KADIMA NEUROPSYCHIATRY INSTITUTE: LAWSUIT SEEKS SPECIFIC PERFORMANCE IN COURT ORDER COMPELLING DEFENDANTS TO CLOSE DEAL ON TERMS IN EXECUTED AGREEMENT

  • KADIMA NEUROPSYCHIATRY INSTITUTE: COMPLAINT ALLEGES NRX WARRANTED IT HAD FUNDS TO CLOSE WHILE CONCEALING IT LACKED COMMITTED FINANCING FOR DEAL

Source text: ID:nBw6JzgM6a

Further company coverage: NRXP.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.